Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
TEK 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
TEK 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
MERTK 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
MERTK 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
AXL 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
AXL 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FLT4 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FLT4 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FLT3 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FLT3 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FLT1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FLT1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
KDR 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
KDR 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
VEGFA 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
VEGFA 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FGFR4 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FGFR4 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FGFR3 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FGFR3 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FGFR2 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FGFR2 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.
Latest Hotspot
8 min read
FGFR1 2026 Target Evaluation Report: Biology, Validation, Competition, IP, and R&D Strategy
13 July 2026
FGFR1 2026 target evaluation report generated from PatSnap Life Sciences MCP workflows, combining biology, validation evidence, clinical competition, IP context, and R&D strategy.